证券代码： 688177 证券简称：百奥泰 公告编号：2025-066 百奥泰生物制药股份有限公司 关于核心技术人员离职的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： YU JIN-CHEN（俞金泉）先生在职期间主要负责公司药物研发工作，目前 已完成与公司研发团队的工作交接，其离职不会对公司的技术研发、产品创新、 核心竞争力与持续经营能力产生不利影响。 YU JIN-CHEN（俞金泉）先生在职期间参与研究并作为发明人申请的专利 等研发成果均为职务成果，该等职务成果所形成的所有权均归属于公司，公司 与YU JIN-CHEN（俞金泉）先生不存在涉及职务成果权属纠纷或潜在纠纷，也 不存在影响公司知识产权权属完整性的情况。 百奥泰生物制药股份有限公司（以下简称"百奥泰"或"公司"）核心技术 人员 YU JIN-CHEN（俞金泉）先生因个人原因于近日向公司申请不再继续返聘 并已办理完成离职手续，离职后不再担任公司任何职务。基于前述原因，公司 不再认定 YU JIN-CHEN（俞金泉）先生为公司核心技术人员。 ...

（记者 王晓波） 每经头条（nbdtoutiao）——重磅解读！中国将不寻求WTO新的特殊和差别待遇，意味着什么？ 每经AI快讯，百奥泰9月30日晚间发布公告称，公司核心技术人员YU JIN-CHEN（俞金泉）先生因个人 原因于近日向公司申请不再继续返聘并已办理完成离职手续，离职后不再担任公司任何职务。基于前述 原因，公司不再认定YU JIN-CHEN（俞金泉）先生为公司核心技术人员。 ...

Group 1: Company Overview - He Yuan Bio is a pioneer in the "rice blood-making" industry, focusing on plant-derived recombinant protein expression technology[7] - The company's core product, recombinant human serum albumin injection (HY1001), was approved for market in July 2025, making it the first recombinant human albumin drug approved in China[12] - The market for human serum albumin in China is projected to grow from 25.8 billion RMB in 2020 to 57 billion RMB by 2030, with a compound annual growth rate (CAGR) of 8.25%[12] Group 2: Financial Metrics - As of September 23, 2025, comparable companies have a median market capitalization of 24.899 billion RMB, with a median price-to-earnings ratio of 26.60 times[20] - He Yuan Bio's revenue from 2022 to H1 2025 was 0.13 billion, 0.24 billion, 0.25 billion, and 0.13 billion RMB, respectively, which is below the average of comparable companies[24] - The company's R&D expenses from 2022 to H1 2025 were 1.10 billion, 1.59 billion, 1.17 billion, and 0.56 billion RMB, with a compound growth rate of 2.81%, slightly above the comparable average of 2.06%[29] Group 3: Market Position and Risks - He Yuan Bio has a unique first-mover advantage in the recombinant human albumin market, with no other similar products approved in China as of August 2025[12] - The company faces risks related to not yet being profitable, as most of its products are still in the R&D phase[43] - There is a risk that the supply of medicinal rice may not meet the demands of large-scale commercial production, which could impact operations[44]

百奥泰生物制药股份有限公司 章 程 二〇二五年九月 | 目录 | | --- | | 第一章 | 总则 1 | | | --- | --- | --- | | 第二章 | 经营宗旨和范围 2 | | | 第三章 | 股份 2 | | | 第一节 | 股份发行 2 | | | 第二节 | 股份增减和回购 4 | | | 第三节 | 股份转让 5 | | | 第四章 | 股东和股东会 6 | | | 第一节 | 股东 6 | | | 第二节 | 控股股东和实际控制人 9 | | | 第三节 | 股东会的一般规定 | 10 | | 第四节 | 股东会的召集 | 12 | | 第五节 | 股东会的提案与通知 | 14 | | 第六节 | 股东会的召开 | 15 | | 第七节 | 股东会的表决和决议 | 18 | | 第五章 | 董事和董事会 23 | | | 第一节 | 董事的一般规定 | 23 | | 第二节 | 董事会 | 26 | | 第三节 | 独立董事 | 31 | | 第四节 | 董事会专门委员会 | 34 | | 第六章 | 高级管理人员 36 | | | 第七章 | 财务会计制度、利润分配和审计 3 ...

证券代码：688177 证券简称：百奥泰 公告编号：2025-065 百奥泰生物制药股份有限公司 关于完成注册地址工商变更登记暨修订《公司章程》 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 百奥泰生物制药股份有限公司（以下简称"公司"或"百奥泰"）分别于 2025 年 8 月 20 日、2025 年 9 月 15 日召开了第三届董事会第二次会议和 2025 年第二 次临时股东会，审议通过了《关于变更注册地址、修订<公司章程>并办理工商 变更登记的议案》，同意根据公司经营发展需要和实际情况，对公司注册地址进 行变更，同时对《百奥泰生物制药股份有限公司章程》（以下简称"《公司章程》"） 的相应条款进行修订。股东会已授权公司管理层及相关授权委托人办理工商变更 登记、章程备案等相关事宜，最终以工商登记机关核准的内容为准。 近日，公司已完成工商变更登记手续，并取得了广州市黄埔区市场监督管理 局换发的营业执照，相关登记信息如下： 统一社会信用代码：91440116751954446J 名称：百奥泰生物制药股份有限公司 类 ...

Core Viewpoint - Baiotai's stock price has shown significant fluctuations in 2023, with a year-to-date increase of 61.92% and a recent decline over the past 20 days [1][2]. Group 1: Stock Performance - As of September 18, Baiotai's stock price rose by 2.02% to 31.38 CNY per share, with a total market capitalization of 12.994 billion CNY [1]. - The stock has experienced a 1.16% increase over the last five trading days, a 5.74% decrease over the last 20 days, and a 27.41% increase over the last 60 days [1]. Group 2: Financial Performance - For the first half of 2025, Baiotai reported a revenue of 442 million CNY, reflecting a year-on-year growth of 9.84% [2]. - The company recorded a net profit attributable to shareholders of -125 million CNY, which is a 47.25% improvement compared to the previous year [2]. Group 3: Company Overview - Baiotai Biopharmaceutical Co., Ltd. was established on July 28, 2003, and went public on February 21, 2020 [1]. - The company's main business activities include the research and production of innovative drugs and biosimilars, with 91.90% of revenue coming from drug sales [1].

Core Insights - The innovation drug industry in China is experiencing significant advancements in product research and development, with companies actively discussing their progress and strategies during the recent performance briefing session [1][2][3]. Group 1: Product Innovation and R&D Progress - Companies like Fudan Zhangjiang and Olin Bio are making notable advancements in their product pipelines, focusing on photodynamic therapy and vaccines for "super bacteria" [1][2]. - Fudan Zhangjiang is developing several drugs targeting conditions such as severe acne and bladder cancer, with ongoing clinical studies [2]. - Olin Bio is researching multiple vaccines for "super bacteria," aiming to initiate clinical trials for flu vaccines by mid-2025 [2]. Group 2: Business Expansion and Market Strategy - Companies are planning to expand their production capacity to support product commercialization, with Baiyao Tai focusing on launching several products that have completed Phase III clinical trials [3][4]. - Shian Bio is set to contribute significant revenue from its various vaccine products, including those for swine fever and other diseases [4]. Group 3: Internationalization and Market Entry - The trend of "going global" is a major focus for the domestic biopharmaceutical industry, with companies exploring diverse international pathways [5]. - Yuantong Bio is awaiting FDA approval for its naloxone nasal spray, marking a step towards international market entry [5]. - Aidi Pharmaceutical has received regulatory approval for its HIV treatment in Zanzibar, highlighting its international expansion efforts [6]. - Companies like Ailis and Haichuang Pharmaceutical are actively pursuing overseas partnerships and clinical trials to enhance their global presence [6][7].

Group 1 - The company will participate in the "2025 Guangdong Investor Collective Reception Day" to enhance interaction with investors [1] - The event will be held online on September 19, 2025, from 15:30 to 17:00 [1] - Company executives will discuss the 2025 semi-annual performance, corporate governance, development strategy, operational status, and sustainable development [1] Group 2 - The second extraordinary general meeting of shareholders was held on September 15, 2025 [3] - All 9 current directors attended the meeting, along with the company secretary and senior management [5] - Three resolutions were passed, including changes to the registered address and the signing of a licensing and commercialization agreement for BAT1806 [6][6]

证券代码： 688177 证券简称： 百奥泰 公告编号：2025-063 百奥泰生物制药股份有限公司 关于参加广东辖区 2025 年投资者网上 集体接待日活动的公告 为进一步加强与投资者的互动交流，百奥泰生物制药股份有限公司（以下 简称"公司"）将参加由广东证监局、广东上市公司协会与深圳市全景网络有限 公司联合举办的"向新提质 价值领航——2025 年广东辖区投资者集体接待日暨 辖区上市公司中报业绩说明会"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP 参与 本次互动交流,活动时间为 2025 年 9 月 19 日（周五）15:30-17:00。 届时公司高管将在线就 2025 年半年度业绩、公司治理、发展战略、经营状 况和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投 资者踊跃参与！ 特此公告。 百奥泰生物制药股份有限公司董事会 2025 年 9 月 16 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实 ...

FANGDA PARTNERS 上海市方达（广州）律师事务所 关于百奥泰生物制药股份有限公司 2025 年第二次临时股东会的法律意见书 致：百奥泰生物制药股份有限公司 上海市方达（广州）律师事务所（以下简称"本所"）是具有中华人民共和国 境内法律执业资格的律师事务所。根据相关法律顾问协议，本所指派律师出席百 奥泰生物制药股份有限公司（以下简称"公司"）2025 年第二次临时股东会（以下 简称"本次股东会"），并就本次股东会的召集和召开程序、参与表决和召集会议 人员的资格、表决程序和表决结果等有关事宜出具本法律意见书。 本法律意见书依据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司股东会规则》及其他相关中华人民共和国境内已公开颁布并生效的法律、 法规、规章及规范性文件（以下合称"中国法律法规"）以及《百奥泰生物制药股 份有限公司章程》（以下称"《公司章程》"）的规定出具。 本法律意见书仅就本次股东会的召集和召开程序、出席会议人员、召集人、 表决程序是否符合相关中国法律法规及《公司章程》的规定以及表决结果是否合 法、有效发表意见，并不对任何中国法律法规以外的国家或地区的法律发表任何 意见。本法律意见 ...